<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479933</url>
  </required_header>
  <id_info>
    <org_study_id>VitDmet</org_study_id>
    <nct_id>NCT01479933</nct_id>
  </id_info>
  <brief_title>Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes</brief_title>
  <acronym>VitDmet</acronym>
  <official_title>Randomized Controlled Trial of Vitamin D Supplementation on Glucose Metabolism in Subjects With Components of the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juho Vainio Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Foundation for Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency is widespread throughout the world, and the deficiency has been
      associated with several chronic diseases, such as cardiovascular diseases and diabetes. In
      Nordic countries, like in Finland, there is a particular variation in vitamin D status, and
      during wintertime, when there is no exposure to ultraviolet-B light from the sun, serum
      concentrations of vitamin D decrease substantially. In Finland, some 40% of middle-aged men
      and one third of women also have some degree of impairment of glucose metabolism.

      The purpose of this trial is to investigate the effects of two different daily doses of
      vitamin D on glucose metabolism in men 60 years of age or older and who are vitamin D
      deficient, have a high body mass index and at least two characteristics of cardio-metabolic
      syndrome.

      Altogether 102 subjects with low serum calcidiol (&lt;60 nmol/L) will be recruited and
      randomized to one of the three groups: 1) 40 µg/d vitamin D3, 2) 80 µg/d vitamin D3 or 3)
      placebo. The supplementation period will last for 6 months from September 2011 to March 2012.

      The main hypotheses of the trial are: (1.) Vitamin D supplementation will improve glucose and
      insulin metabolism in people with a low baseline vitamin D status, in a dose-dependent
      manner. (2.) Vitamin D supplementation will have an effect on the expression of genes
      involved in glucose and insulin metabolism and inflammation. (3.) Vitamin D supplementation
      will have an effect on epigenetic changes in key genes participating in vitamin D metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Six months</time_frame>
    <description>Change in insulin sensitivity measured by oral glucose tolerance test at baseline and after 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood mononuclear cell gene expression</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline to six months</time_frame>
    <description>Change in inflammation measured as serum cytokines and adipose tissue inflammation at baseline and after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue gene expression</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Prediabetic State</condition>
  <condition>Overweight</condition>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>Vitamin D 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 40 micrograms (1600 IU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 80 micrograms (3200 IU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 40 micrograms (1600 IU) per day</description>
    <arm_group_label>Vitamin D 40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D 80</intervention_name>
    <description>Vitamin D3 80 micrograms (3200 IU) per day</description>
    <arm_group_label>Vitamin D 80</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 60 years or older

          -  Serum calcidiol &lt;75 nmol/L

          -  Body mass index 25-35 kg/m2

          -  Impaired fasting glucose or impaired glucose tolerance (fasting glucose 5.6-7.0 mmol/L
             or 2h oral glucose tolerance test glucose 7.8-11.0 mmol/L)

        Exclusion Criteria:

          -  Any chronic disease and condition, which may hamper to follow the intervention
             protocol (such as alcohol abuse)

          -  Any chronic disease or therapy which may mask or interact with the investigated
             effects (such as diabetes or systemic corticosteroid therapy)

          -  Any disease or state that raises a vitamin D related safety concern (such as chronic
             liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous
             diseases such as active chronic tuberculosis or Wegener's granulomatosis)

          -  Use of supplements yielding vitamin D over 20 µg/d and unwillingness to discontinue
             the use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomi-Pekka Tuomainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland, Kuopio Campus</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.uef.fi</url>
    <description>University of Eastern Finland</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <last_update_submitted>March 3, 2013</last_update_submitted>
  <last_update_submitted_qc>March 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Tomi-Pekka Tuomainen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>supplementation</keyword>
  <keyword>prediabetic state</keyword>
  <keyword>obesity</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>gene expression</keyword>
  <keyword>transcriptomics</keyword>
  <keyword>epigenomics</keyword>
  <keyword>immunological function</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>peripheral mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

